Epoetin beta

Epoetin beta

Clinical data
Pronunciation	/ɛˈpoʊ.ɪtɪn/
Trade names	Neorecormon, Betapoietin, others[1]
AHFS/Drugs.com	International Drug Names
License data	EU EMA: by INN
Pregnancy category	AU: B3[2]
Routes of administration	Intravenous, subcutaneous
ATC code	B03XA01 (WHO)
Legal status
Legal status	AU: S4 (Prescription only)[2] EU: Rx-only[3] In general: ℞ (Prescription only)
Identifiers
CAS Number	122312-54-3^N
DrugBank	DB00016^Y
ChemSpider	none
UNII	64FS3BFH5W
KEGG	D03232^N
^NY (what is this?)  (verify)

Epoetin beta (INN), sold under the brand name Neorecormon among others, is a synthetic, recombinant^[4] form of erythropoietin, a protein that promotes the production of red blood cells. It is an erythropoiesis-stimulating agent (ESA) that is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy.

It is on the World Health Organization's List of Essential Medicines.^[5]

Chemistry

Epoetin beta is a recombinant form of human erythropoietin which is produced in Chinese hamster ovary cells. It has the same protein sequence as natural human erythropoietin, being composed of 165 amino acids with about 30 KDa molecular weight.^[6]

History

Erythropoietin (EPO) is a hormone produced in the kidneys. The existence of this hormone has been known since 1906, when scientists first started isolating it, and since the 1980s, a recombinant version of the hormone has been available for use in medical treatment.^{[citation needed]}

See also

• Epoetin alfa
• Epoetin theta

References

1. Centers for Medicare and Medicaid Services: Erythrocyte Stimulating Agents Archived 2017-06-07 at the Wayback Machine. Retrieved 15 February 2017.
2. Australian product information Archived 2023-01-09 at the Wayback Machine guildlink.com.au
3. "NeoRecormon EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 9 January 2023. Retrieved 9 January 2023.
4. Dunn CJ, Markham A (February 1996). "Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure". Drugs. 51 (2): 299–318. doi:10.2165/00003495-199651020-00008. PMID 8808169. S2CID 46985336.
5. World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
6. Medsafe: Neorecormon Datasheet Archived 2020-08-30 at the Wayback Machine

Further reading

• Jenkins JK (2007-06-26). "Erythropoiesis-Stimulating Agents (ESA)". U.S. Food and Drug Administration (FDA). Archived from the original on 5 March 2010.

External links

• "Epoetin beta". Drug Information Portal. U.S. National Library of Medicine.